Lilly expands infectious disease portfolio with three strategic acquisitions
Lilly has announced three acquisitions targeting viral and bacterial pathogens associated with significant health risks.
Asset / Drug
Drug and asset intelligence for Curevo with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.